Zoe N. Zussa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zoe N. Zussa has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Kelly Louise Williams
Macquarie University Motor Neuron Disease Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia
4 shared publications - Dominic Brock Rowe
MND Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia
3 shared publications - Lyndal Henden
Macquarie University Motor Neuron Disease Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia
3 shared publications - Sandrine Chan Moi Fat
Macquarie University
3 shared publications Carol M. Y. Lee
Macquarie University
2 shared publications- Garth A. Nicholson
Molecular Medicine Laboratory, Concord Repatriation General Hospital, Sydney, Australia
2 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Springer Nature in Journal of Human Genetics
- p. 1-8
Characterising the motif composition and allele length distribution of ZFHX3 GGC repeat expansions in amyotrophic lateral sclerosis
A pathogenic GGC repeat expansion in zinc finger homeobox 3 ( ZFHX3 ), encoding a pure polyglycine (polyG) tract, causes spinocerebellar ataxia type 4 (SCA4). Intermediate expansions of other SCA loci have been implicated in amyotrophic lateral sclerosis (ALS), while repeat motif composition is recognised to influence pathogenicity in neurodegenerative diseases. Given the genetic pleiotropy between ALS and SCA, we evaluated whether ZFHX3 GGC expansions are associated with ALS and characterised repeat motif composition. ZFHX3 GGC repeat sizes were genotyped using ExpansionHunter in short-read whole-genome sequencing data from ALS cases and healthy controls of European ancestry. Repeat sizes were visually inspected using REViewer, and motif configurations were manually derived from a subset. Receiver operating characteristic analysis and Youden’s J statistic identified a candidate repeat size threshold. Logistic regression tested associations of repeat length and motif composition with ALS, while regression models assessed clinical phenotypes. Across 5785 ALS cases and 7982 controls, no association was observed between ZFHX3 expansions and ALS risk. Longer alleles showed a nominal association with later disease onset, however this did not remain significant after Bonferroni correction. Among 802 ALS cases and 800 controls, 50 distinct motif compositions were identified, including 11 encoding pure polyG tracts characteristic of pathogenic SCA4 expansions; none were associated with ALS. Although no association with ALS was observed, this study established the dynamic nature of ZFHX3 repeat motif composition and configuration. Variation within and between repeat sizes, including pure polyG repeats, supports consideration of motif composition alongside allele length when evaluating neurodegenerative disease risk.
- 15 September 2026
- Published by Springer Nature in Journal of Human Genetics
- p. 1-8
Open AccessCharacterising the motif composition and allele length distribution of ZFHX3 GGC repeat expansions in amyotrophic lateral sclerosis
A pathogenic GGC repeat expansion in zinc finger homeobox 3 ( ZFHX3 ), encoding a pure polyglycine (polyG) tract, causes spinocerebellar ataxia type 4 (SCA4). Intermediate expansions of other SCA loci have been implicated in amyotrophic lateral sclerosis (ALS), while repeat motif composition is recognised to influence pathogenicity in neurodegenerative diseases. Given the genetic pleiotropy between ALS and SCA, we evaluated whether ZFHX3 GGC expansions are associated with ALS and characterised repeat motif composition. ZFHX3 GGC repeat sizes were genotyped using ExpansionHunter in short-read whole-genome sequencing data from ALS cases and healthy controls of European ancestry. Repeat sizes were visually inspected using REViewer, and motif configurations were manually derived from a subset. Receiver operating characteristic analysis and Youden’s J statistic identified a candidate repeat size threshold. Logistic regression tested associations of repeat length and motif composition with ALS, while regression models assessed clinical phenotypes. Across 5785 ALS cases and 7982 controls, no association was observed between ZFHX3 expansions and ALS risk. Longer alleles showed a nominal association with later disease onset, however this did not remain significant after Bonferroni correction. Among 802 ALS cases and 800 controls, 50 distinct motif compositions were identified, including 11 encoding pure polyG tracts characteristic of pathogenic SCA4 expansions; none were associated with ALS. Although no association with ALS was observed, this study established the dynamic nature of ZFHX3 repeat motif composition and configuration. Variation within and between repeat sizes, including pure polyG repeats, supports consideration of motif composition alongside allele length when evaluating neurodegenerative disease risk.
- Open Access
Motor neuron disease in rural Australia: a population-based observational study of epidemiology, clinical characteristics and regional variation
Objectives: To characterise the epidemiology, clinical features, and geographic distribution of motor neuron disease (MND) within a rural Australian population. Design: Retrospective, population-based epidemiology study. Setting: Western New South Wales Local Health District (WNSWLHD), Australia, from 1 January 2023 to 31 December 2025. Participants: Fifty-one individuals diagnosed with MND identified through Central West Neurology and Neurosurgery, Orange Palliative Care Service, and the WNSWLHD Neurodegenerative Community Care Team. Main outcome measures: Crude and age-standardised incidence, prevalence and mortality rates of MND; demographic and clinical characteristics; geographic distribution of prevalence. Results: The all-age crude incidence of MND was 4.01 per 100,000 person-years (95% CI, 2.78-5.60), prevalence was 8.14 per 100,000 population (95% CI, 6.33-10.30), and mortality was 3.77 per 100,000 person-years (95% CI, 2.58-5.33). Females comprised 51% of patients and showed higher incidence, prevalence and mortality than males. Bulbar-onset MND accounted for 47% of patients, including 61% of females. MND prevalence varied across the health district, with the highest burden observed in central and south-eastern regional areas. Patients travelled on average 139 km to access neurological care, with a diagnostic delay of nine months. Conclusions: MND incidence and mortality are high in this rural Australian population compared with national and global estimates, with an overrepresentation of bulbar-onset disease and altered sex distribution. These findings provide an important baseline for population-level MND surveillance, following the introduction of mandatory notification in NSW, Australia. Findings also highlight the need for strengthened rural healthcare services, and further research of potential genetic and environmental contributors to MND risk.
Open AccessMotor neuron disease in rural Australia: a population-based observational study of epidemiology, clinical characteristics and regional variation
Objectives: To characterise the epidemiology, clinical features, and geographic distribution of motor neuron disease (MND) within a rural Australian population. Design: Retrospective, population-based epidemiology study. Setting: Western New South Wales Local Health District (WNSWLHD), Australia, from 1 January 2023 to 31 December 2025. Participants: Fifty-one individuals diagnosed with MND identified through Central West Neurology and Neurosurgery, Orange Palliative Care Service, and the WNSWLHD Neurodegenerative Community Care Team. Main outcome measures: Crude and age-standardised incidence, prevalence and mortality rates of MND; demographic and clinical characteristics; geographic distribution of prevalence. Results: The all-age crude incidence of MND was 4.01 per 100,000 person-years (95% CI, 2.78-5.60), prevalence was 8.14 per 100,000 population (95% CI, 6.33-10.30), and mortality was 3.77 per 100,000 person-years (95% CI, 2.58-5.33). Females comprised 51% of patients and showed higher incidence, prevalence and mortality than males. Bulbar-onset MND accounted for 47% of patients, including 61% of females. MND prevalence varied across the health district, with the highest burden observed in central and south-eastern regional areas. Patients travelled on average 139 km to access neurological care, with a diagnostic delay of nine months. Conclusions: MND incidence and mortality are high in this rural Australian population compared with national and global estimates, with an overrepresentation of bulbar-onset disease and altered sex distribution. These findings provide an important baseline for population-level MND surveillance, following the introduction of mandatory notification in NSW, Australia. Findings also highlight the need for strengthened rural healthcare services, and further research of potential genetic and environmental contributors to MND risk.
- Open Access
- 24 March 2026
- Published by Wiley in Medical Journal of Australia
- Vol. 224 (3) , e70168
Motor Neuron Disease Mortality Trends in Australia From 1986 to 2023: A Population‐Based Study
Objectives: To analyse longitudinal change in motor neuron disease (MND) mortality in Australia from 1986 to 2023. Design: Australian population‐based study of MND mortality. Setting: All MND mortality and Australian population data from 1 January 1986 to 31 December 2023 were obtained from the Australian Bureau of Statistics. Main Outcome Measures: MND mortality records were analysed, and certified deaths were summarised by year of registration. MND mortality rates, 95% confidence intervals (CIs) and Joinpoint regression trends were calculated. Data were further subset by demographic and geographical categories to report Australian MND mortality by age group, sex, state/territory location and remoteness areas classification. Results: In Australia, the total number of MND deaths more than tripled over the past 37 years, from 238 in 1986 to 781 in 2023. The unadjusted mortality rate in 1986 was 1.49 (95% CI , 1.30–1.69) per 100,000 population and increased to 2.93 (95% CI , 2.73–3.14) per 100,000 population by 2023. After age standardisation, the annual percentage change across 1986–2023 was determined to be 0.47% (95% confidence limit, 0.16–0.86). Joinpoint modelling suggests a more recent reduction in adjusted mortality rates. In 2023, MND accounted for 0.43% of all‐cause deaths in Australia, increasing from 0.21% in 1986. The number of MND deaths in Australia peaked at age 70–79 years. MND mortality was higher among men than women (rate ratio, 1.41; 95% CI , 1.33–1.51). MND mortality rates were similar among New South Wales, Victoria and Queensland (2.93, 3.08 and 2.85 per 100,000 population, respectively), with higher rates in South Australia and Tasmania (3.44 and 4.12 per 100,000 population, respectively). MND mortality rates were higher in inner and outer regional areas (3.90 and 3.24 per 100,000 population, respectively) compared with major cities (2.79 per 100,000 population). Conclusions: Adjusted MND mortality rates in Australia increased over 37 years.
- 24 March 2026
- Published by Wiley in Medical Journal of Australia
- Vol. 224 (3) , e70168
Open AccessMotor Neuron Disease Mortality Trends in Australia From 1986 to 2023: A Population‐Based Study
Objectives: To analyse longitudinal change in motor neuron disease (MND) mortality in Australia from 1986 to 2023. Design: Australian population‐based study of MND mortality. Setting: All MND mortality and Australian population data from 1 January 1986 to 31 December 2023 were obtained from the Australian Bureau of Statistics. Main Outcome Measures: MND mortality records were analysed, and certified deaths were summarised by year of registration. MND mortality rates, 95% confidence intervals (CIs) and Joinpoint regression trends were calculated. Data were further subset by demographic and geographical categories to report Australian MND mortality by age group, sex, state/territory location and remoteness areas classification. Results: In Australia, the total number of MND deaths more than tripled over the past 37 years, from 238 in 1986 to 781 in 2023. The unadjusted mortality rate in 1986 was 1.49 (95% CI , 1.30–1.69) per 100,000 population and increased to 2.93 (95% CI , 2.73–3.14) per 100,000 population by 2023. After age standardisation, the annual percentage change across 1986–2023 was determined to be 0.47% (95% confidence limit, 0.16–0.86). Joinpoint modelling suggests a more recent reduction in adjusted mortality rates. In 2023, MND accounted for 0.43% of all‐cause deaths in Australia, increasing from 0.21% in 1986. The number of MND deaths in Australia peaked at age 70–79 years. MND mortality was higher among men than women (rate ratio, 1.41; 95% CI , 1.33–1.51). MND mortality rates were similar among New South Wales, Victoria and Queensland (2.93, 3.08 and 2.85 per 100,000 population, respectively), with higher rates in South Australia and Tasmania (3.44 and 4.12 per 100,000 population, respectively). MND mortality rates were higher in inner and outer regional areas (3.90 and 3.24 per 100,000 population, respectively) compared with major cities (2.79 per 100,000 population). Conclusions: Adjusted MND mortality rates in Australia increased over 37 years.
- Open Access
Characterising the motif composition and allele length distribution of ZFHX3 GGC repeat expansions in amyotrophic lateral sclerosis
Background and objectives: A pathogenic GGC repeat expansion in the zinc finger homeobox 3 ( ZFHX3 ) gene, encoding a pure polyglycine tract, is the cause of spinocerebellar ataxia type 4 (SCA4). Intermediate expansions of other SCA loci contribute to the risk of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease involving the progressive loss of motor neurons. There is increasing awareness of the role of short tandem repeat (STR) motif composition and configuration in disease pathogenicity. Given the genetic pleiotropy between ALS and SCA, this study aimed to evaluate whether ZFHX3 GGC expansions were associated with ALS and to characterise repeat motif composition. Methods: ExpansionHunter v5 was used to genotype ZFHX3 GGC repeat sizes in short-read whole genome sequencing data from people with ALS and healthy controls of European ancestry. Repeat sizes were visually inspected using REViewer v2. Repeat motif configurations of Australian ALS cases and healthy controls were manually derived from REViewer images. Receiver operating characteristic (ROC) curve analysis and Youden’s J statistic were performed to find a candidate repeat size threshold for association testing. Fisher’s exact tests were performed to evaluate the associations of repeat size and motif composition with disease status. Results: Analysis of 5,785 people with ALS and 7,982 healthy controls found no association between ZFHX3 GGC repeat expansions and disease risk. Fifty unique repeat motif compositions were identified across 802 people with ALS and 800 healthy controls. Of these, eleven distinct configurations coded a pure polyglycine tract which, when expanded, is canonical to SCA4, though no association with ALS was found. Discussion: Although no association was observed between ZFHX3 GGC repeat expansions and ALS, this study established the dynamic nature of ZFHX3 repeat motif composition and configuration. Unique motif compositions were identified both within and between repeat sizes, including the presence of pure polyglycine repeats. Consideration of repeat motif composition and configuration, in addition to repeat allele length, may be important for assessing neurodegenerative disease risk.
Open AccessCharacterising the motif composition and allele length distribution of ZFHX3 GGC repeat expansions in amyotrophic lateral sclerosis
Background and objectives: A pathogenic GGC repeat expansion in the zinc finger homeobox 3 ( ZFHX3 ) gene, encoding a pure polyglycine tract, is the cause of spinocerebellar ataxia type 4 (SCA4). Intermediate expansions of other SCA loci contribute to the risk of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease involving the progressive loss of motor neurons. There is increasing awareness of the role of short tandem repeat (STR) motif composition and configuration in disease pathogenicity. Given the genetic pleiotropy between ALS and SCA, this study aimed to evaluate whether ZFHX3 GGC expansions were associated with ALS and to characterise repeat motif composition. Methods: ExpansionHunter v5 was used to genotype ZFHX3 GGC repeat sizes in short-read whole genome sequencing data from people with ALS and healthy controls of European ancestry. Repeat sizes were visually inspected using REViewer v2. Repeat motif configurations of Australian ALS cases and healthy controls were manually derived from REViewer images. Receiver operating characteristic (ROC) curve analysis and Youden’s J statistic were performed to find a candidate repeat size threshold for association testing. Fisher’s exact tests were performed to evaluate the associations of repeat size and motif composition with disease status. Results: Analysis of 5,785 people with ALS and 7,982 healthy controls found no association between ZFHX3 GGC repeat expansions and disease risk. Fifty unique repeat motif compositions were identified across 802 people with ALS and 800 healthy controls. Of these, eleven distinct configurations coded a pure polyglycine tract which, when expanded, is canonical to SCA4, though no association with ALS was found. Discussion: Although no association was observed between ZFHX3 GGC repeat expansions and ALS, this study established the dynamic nature of ZFHX3 repeat motif composition and configuration. Unique motif compositions were identified both within and between repeat sizes, including the presence of pure polyglycine repeats. Consideration of repeat motif composition and configuration, in addition to repeat allele length, may be important for assessing neurodegenerative disease risk.